TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

por Cabioglu, Neslihan, Onder, Semen, Oner, Gizem, Karatay, Hüseyin, Tukenmez, Mustafa, Muslumanoglu, Mahmut, İgci, Abdullah, Eralp, Yeşim, Aydiner, Adnan, Saip, Pınar, Yavuz, Ekrem, Ozmen, Vahit
Publicado 2021

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

por Oner, Gizem, Önder, Semen, Karatay, Hüseyin, Ak, Naziye, Tükenmez, Mustafa, Müslümanoğlu, Mahmut, İğci, Abdullah, Dincçağ, Ahmet, Özmen, Vahit, Aydiner, Adnan, Yavuz, Ekrem, Cabioğlu, Neslihan
Publicado 2021

Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

por Oner, Gizem, Önder, Semen, Karatay, Hüseyin, Ak, Naziye, Tükenmez, Mustafa, Müslümanoğlu, Mahmut, İğci, Abdullah, Dincçağ, Ahmet, Özmen, Vahit, Aydiner, Adnan, Yavuz, Ekrem, Cabioğlu, Neslihan
Publicado 2023

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer

por Cabioglu, Neslihan, Bayram, Aysel, Emiroglu, Selman, Onder, Semen, Karatay, Huseyin, Oner, Gizem, Tukenmez, Mustafa, Muslumanoglu, Mahmut, Igci, Abdullah, Aydiner, Adnan, Saip, Pinar, Yavuz, Ekrem, Ozmen, Vahit
Publicado 2023